Business
argenx Highlights 2026 Strategic Priorities
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; thre
About this update from Argenx Se
[{"type":"image","alt":"argenx SE","displaySize":"","headline":null,"caption":"argenx SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_55.hEettGltaZ5cA.9xTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales ","length":151,"tagName":"p"},{"type":"text","content":"VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026","length":146,"tagName":"p"},{"type":"text","content":"Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches","length":137,"tagName":"p"},{"type":"text","content":"Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end","length":169,"tagName":"p"},{"type":"text","content":"January 12, 2026, 7:00 a.m. CETAmsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported preliminary financial results for the full-year 2025, including global product net sales, and announced its strategic priorities for 2026.","length":367,"tagName":"p"},{"type":"text","content":"“argenx enters 2026 in a position of strength, delivering meaningful impact to approximately 19,000 patients globally while advancing a world-class pipeline toward Vision 2030,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “With VYVGART leading the growth of all biologics in MG and CIDP, we are proving the power of our approach: to redefine treatment paradigms through disciplined evidence generation and to redefine patient outcomes with medicines that are both more effective and more convenient. This same playbook will guide our future,...